Investigating how tumor-macrophage hybrid cells contribute to prostate cancer spread
The role of tumor-macrophage hybrid cells in prostate cancer metastasis
This study is looking into how certain hybrid cells made from tumors and immune cells help prostate cancer become tougher and spread, with the hope of finding new ways to treat patients who have advanced cancer that doesn't respond to regular treatments.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11077798 on NIH RePORTER |
What this research studies
This research explores the role of tumor-macrophage hybrid cells in the progression of prostate cancer, particularly in cases where the cancer becomes resistant to standard treatments. The study aims to understand how these hybrid cells evade the immune system and adapt to survive in the bloodstream, which may lead to metastasis. By examining the unique characteristics of these cells, the research seeks to uncover new mechanisms that contribute to the aggressive nature of advanced prostate cancer. Patients may benefit from insights that could lead to more effective treatments targeting these hybrid cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced or metastatic prostate cancer, particularly those whose tumors have become resistant to androgen signaling inhibitors.
Not a fit: Patients with early-stage prostate cancer or those whose cancer is not resistant to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with advanced prostate cancer.
How similar studies have performed: While the role of tumor-macrophage hybrid cells in cancer is a relatively novel area of investigation, preliminary studies have shown promising results in understanding their impact on tumor progression.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Huang, Tim H.-M. — University of Texas Hlth Science Center
- Study coordinator: Huang, Tim H.-M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.